Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FBPZK
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,222
Award facts
- Contract value 100% obligated
- $12,222.32 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a $12,222.32 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml auto-injector vials. The delivery order, awarded on December 23, 2025, with an ultimate completion date of January 15, 2026, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. DMS Pharmaceutical Group was selected as the prime contractor with no identified subcontractors, leveraging its established position as a critical supplier within the Department of Defense pharmaceutical supply chain.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to provide pharmaceutical products and medical consumables to military healthcare facilities worldwide. The underlying IDC, awarded to DMS Pharmaceutical Group on November 13, 2025, carries a $499,999,999 ceiling value and extends through December 31, 2036, with a 30-month base period and three 30-month option periods. As a regional prime vendor contractor under this program, DMS Pharmaceutical Group is positioned to fulfill diverse pharmaceutical requirements supporting Department of Defense healthcare operations globally, with Xolair representing one component of the company's extensive product portfolio encompassing branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals.
Quick answers
Who was awarded contract SPE2DR26FBPZK?
SPE2DR26FBPZK was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 23, 2025.
How much is contract SPE2DR26FBPZK worth?
The government has obligated $12,222 on SPE2DR26FBPZK.
Is contract SPE2DR26FBPZK an order under another contract?
Yes. SPE2DR26FBPZK is a delivery order under SPE2DR25D9304, an indefinite delivery contract.
Was contract SPE2DR26FBPZK competed?
The extent of competition for SPE2DR26FBPZK was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award